Over the last eight months, the US Federal Trade Commission (FTC) has focused on what it characterizes as “improper” Orange Book listings and the impacts of such listings on generic entry....more
Biologic drug makers will soon have to alert the Federal Trade Commission and Department of Justice of agreements, including patent litigation settlements, they reach with biosimilar applicants. The new reporting requirement...more
1. Transition to a Trump Administration is top of the agenda -
President-elect Donald Trump's DOJ and FTC transition team appointments and public short list of candidates to run the agencies indicate that antitrust...more
1/12/2017
/ Antitrust Division ,
Big Data ,
CFIUS ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Hiring & Firing ,
Human Resources Professionals ,
Mergers ,
Pharmaceutical Industry ,
Trump Administration ,
UK Competition and Markets Authority (CMA) ,
Wage-Fixing
On March 30 the US Federal Trade Commission filed suit in federal court alleging that settlements of patent litigation in the pharmaceutical industry in which a pioneer firm agrees not to market an "authorized generic"...more
4/7/2016
/ Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
No-AG Agreement ,
Patent Litigation ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Reverse Payment Settlement Agreements
Attention in the US during 2016 will be on the presidential campaign, and the election in November will bring a change in the "antitrust guard" at the top of the DOJ and FTC – even if a Democrat wins – that will drive the...more
1/12/2016
/ China ,
Corporate Counsel ,
Criminal Penalties ,
Department of Justice (DOJ) ,
Disgorgement ,
Drug Pricing ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
FRAND ,
Mergers ,
MOFCOM ,
Patent Assertion Entities ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Price-Fixing ,
Standard Essential Patents ,
Technology Sector
Recent antitrust challenges to pharmaceutical companies' efforts to transition patients from drugs nearing the end of their patent life to next-generation drugs have increased the risk of pursuing such "product hopping"...more